🔗 Share this article

The first new treatments for gonorrhoea in a generation are being described as a "major milestone" in the effort against drug-resistant strains of the infection, according to health experts.

An International Public Health Issue

Cases of gonorrhoea are escalating globally, with data suggesting more than 82 million instances annually. Especially elevated rates are observed in Africa and nations within the World Health Organization's designated area, which includes Mongolia and China to New Zealand. Within England, cases have hit a all-time high, while rates across Europe in 2023 were triple the level compared to figures for 2014.

“The authorization of new treatments for gonorrhoea is an critical and opportune step in the reality of rising global incidence, escalating drug resistance and the highly restricted available drugs currently available.”

Medical experts are increasingly worried about the increase in antibiotic-resistant strains. The global health body has listed it as a "critical concern". Recent surveillance revealed that resistance to standard treatments like cefixime and ceftriaxone jumped significantly between 2022 and 2024.

Two New Treatment Options Secure Clearance

One new antibiotic, alternatively called a brand name, was authorized by the American regulatory agency in mid-December for combating gonorrhoea. This STI can lead to serious health problems, including the inability to conceive. Experts believe that targeted use of this new drug will help hinder the emergence of superbugs.

Gepotidacin, developed by the drugmaker GlaxoSmithKline, also received approval in close succession. This treatment, which is also used to treat urinary tract infections, was shown in trials to be successful in treating drug-resistant strains of the gonorrhoea bacteria.

An Innovative Partnership

Zoliflodacin was the result of a unique collaborative effort for medication research. The charitable organization Global Antibiotic Research & Development Partnership partnered with the drug firm its industry partner to bring it to fruition.

“This authorization marks a major breakthrough in the therapy of highly resistant gonorrhoea, which until now has been outpacing our drug pipeline.”

Testing Data and Worldwide Availability

According to data released by a prominent scientific publication, the new drug successfully treated over nine in ten of cases of the STI. This puts it on an comparable level with the typical regimen, which combines an injection and a pill. The research involved over 900 volunteers from various regions including the United States, Thailand, South Africa, and European nations.

As part of the agreement of its unique model, GARDP has the ability to register and commercialise the drug in many low-income and middle-income countries.

Clinicians treating patients have expressed optimism. The availability of a easy-to-administer therapy such as this is hailed as a "game-changer" for managing the epidemic. This is viewed as vital to lessen the impact of the disease for individuals and to prevent the spread of extremely resistant gonorrhoea worldwide.